Discontinued — last reported Q3 '23
Stryker Interest Paid remained flat by 0.0% to $99.00M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 11.2%, from $89.00M to $99.00M. Over 3 years (FY 2021 to FY 2024), Interest Paid shows an upward trend with a 6.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
cf_interest_paid| FY'21 | FY'22 | FY'23 | FY'24 | |
|---|---|---|---|---|
| Value | $325.00M | $324.00M | $356.00M | $396.00M |
| YoY Change | — | -0.3% | +9.9% | +11.2% |
We use cookies for analytics. See our Privacy and Cookie Policy.